Therapeutics and Diagnostics for Women's Disorders

Table of Contents

Therapeutics and Diagnostics for Women' s Disorders

Chapter-1: SUMMARY

• CHAPTER TWO: SUMMARY
• SUMMARY TABLE U.S. MARKET FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN' S DISORDERS BY SEGMENT, THROUGH 2013 ($ MILLIONS)
• SUMMARY FIGURE U.S. MARKET FORECAST FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN' S DISORDERS BY SEGMENT, 2006 - 2013 ($ MILLIONS)

Chapter-2: INDUSTRY OVERVIEW

• DEFINITION OF WOMEN' S DISORDERS
• IMPORTANCE OF THE INDUSTRY AND DEMOGRAPHICS
  • TABLE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)
  • FIGURE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)
  • TABLE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
  • FIGURE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
  • TABLE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)
  • FIGURE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)
• HISTORY OF THE INDUSTRY AND RESPONSE TO WOMEN' S HEALTHCARE NEEDS
• REGULATORY ENVIRONMENT
• EFFECTS OF AGING
  • FIGURE 4 FEMALE LIKELIHOOD OF GETTING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2008 (%)
  • FIGURE 4 (CONTINUED)
• CONTRACEPTIVE INSURANCE COVERAGE
  • TABLE 4 INSURANCE COVERAGE OF CONTRACEPTIVES BY STATE
• CONTRACEPTIVE USE IN TEENS INCREASES
• NEW USE FOR CONTRACEPTIVES
• NEW USE FOR CONTRACEPTIVES (CONTINUED)
• AGING AND INFERTILITY
• CONTRACEPTIVE PATCH LINKED TO DEATHS
• WOMEN AND SEXUAL HEALTH
• WOMEN AND SEXUAL HEALTH (CONTINUED)
• INCIDENCE OF SEXUAL DYSFUNCTION
• Incidence of Sexual Dysfunction (Continued)
• VASCULAR TREATMENTS AND SEXUAL DYSFUNCTION
• DIAGNOSTICS
• NEW DEVELOPMENTS IN SEXUAL DYSFUNCTION TREATMENTS FOR WOMEN
• Alista
  • TABLE 5 U.S. SEXUAL DYSFUNCTION PRODUCTS FOR WOMEN IN DEVELOPMENT, 2008
• SEXUAL DYSFUNCTION IN CANCER
• INFERTILITY AND CANCER
• CHEMOTHERAPY
• RADIATION
• PREVENTION STRATEGIES
• MARKETING AND WOMEN
• COUNTERFEIT PHARMACEUTICALS
• GENERIC PARTICIPATION
  • TABLE 6 U.S. PRESCRIPTION GENERIC DRUG APPROVALS FOR CONSTRACEPTION BY COMPANY AND APPROVAL DATE, 2003 - 2008
• INTERNATIONAL ISSUES

Chapter-3: AUTOIMMUNE DISEASES

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 7 U.S. MARKET FORECAST FOR AUTOIMMUNE DISEASES BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 8 MANUFACTURERS OF AUTOIMMUNE DISEASE PRODUCTS, 2008
  • TABLE 9 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)
  • FIGURE 5 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 (%)
• MARKET BY DISEASE TYPE
• CHRONIC FATIGUE SYNDROME
• Incidence and Mortality
• Market Indicators
• Market Indicators (Continued)
• Market Indicators (Continued)
• FIBROMYALGIA
• Incidence
• Diagnostics
• Pain in 11 of 18 Tender Point Sites on Digital Palpation
• Pain in 11 of 18 ..... (Continued)
• Market Indicators
• Market Indicators (Continued)
• Current Market Participants
• MYASTHENIA GRAVIS
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Current Market Participants
• SJOGREN' S SYNDROME
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Current Market Participants
• SYSTEMIC LUPUS ERYTHEMATOSUS
• Systemic Lupus ..... (Continued)
• Incidence and Mortality
• Diagnostics
• Diagnostics (Continued)
• Market Indicators
• IN DEVELOPMENT
• PRESTARA
• AMPLIGEN
• RIQUENT
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 10 U.S. AUTOIMMUNE DISEASE PRODUCTS IN DEVELOPMENT, 2008
  • TABLE 10 (CONTINUED)

Chapter-4: WOMEN' s CANCERS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 11 U.S. MARKET FORECAST FOR WOMEN' S CANCER BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 12 MANUFACTURERS OF WOMEN' S CANCER PRODUCTS, 2008
  • TABLE 13 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)
  • FIGURE 6 SUMMARY OF CANCER MARKET BY COMPETITOR REVENUES, 2008 (%)
• MARKET BY TYPE OF CANCER
• BREAST CANCER
  • TABLE 14 TNM CLASSIFICATIONS OF BREAST CANCERS
  • TABLE 15 5-YEAR SURVIVAL RATE BASED ON STAGE OF BREAST CANCER FOR WOMEN IN THE U.S, 2008 (%)
• Incidence and Mortality
  • TABLE 16 TOTAL YEARLY CASES AND DEATHS FOR BREAST CANCER IN WOMEN WORLDWIDE, 2008
• Diagnostics
• Diagnostics (Continued)
• Market Indicators
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Current Market Participants
• CERVICAL CANCER
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Current Market Participants
• ENDOMETRIAL CANCER
• Incidence and Mortality
• Market Indicators
• Current Market Participants
• OVARIAN CANCER
• Incidence and Mortality
• Diagnostics
• Market Indicators
• Market Indicators (Continued)
• Current Market Participants
• IN DEVELOPMENT
• 572016
• ACTIMMUNE
• ARZOXIFENE
• ATAMESTANE
• FASLODEX
• IMC-C2259
• FABLYN
• OVAREX
• TEMSIROLIMUS
• THERATOPE
• OPAXIO
• A FEW SELECT U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 17 SELECTED WOMEN' S CANCER PRODUCTS IN DEVELOPMENT IN THE U.S., 2008

Chapter-5: GYNECOLOGICAL INFECTIONS AND SEXUALLY TRANSMITTED DISEASES

• U.S. MARKET OVERVIEW
  • TABLE 18 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS
• MARKET SIZE
  • TABLE 19 U.S. MARKET FORECAST FOR GYNECOLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 20 U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 7 SUMMARY OF U.S. GYNECOLOGICAL DISEASES AND INFECTIONS MARKET BY COMPETITOR REVENUES, 2008 (%)
  • TABLE 21 MANUFACTURERS OF GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS, 2008
  • TABLE 21 (CONTINUED)
• MARKET BY DISEASE TYPE
• BACTERIAL VAGINOSIS
• Incidence
• Market Indicators
• CANDIDIASIS
• Incidence
• Market Indicators
• Current Market Participants
• CERVICAL DYSPLASIA
• Incidence
• CHLAMYDIA
• Incidence
• Diagnostics
• Market Indicators
• CONDYLOMA
• Incidence
• Market Indicators
• DYSMENORRHEA
• Incidence
• ENDOMETRIOSIS
• Incidence
• Market Indicators
• FIBROIDS
• Incidence
• Market Indicators
• GENITAL HERPES
• Incidence
• Diagnostics
• Market Indicators
• Current Market Participants
• PELVIC INFLAMMATORY DISEASE
• Incidence
• Market Indicators
• IN DEVELOPMENT
• HUMAN PAPILLOMAVIRUS
• LOW DOSE ORAL INTERFERON-ALPHA
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 22 GYNECOLOGICAL DISEASE AND INFECTION PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
  • TABLE 22 (CONTINUED)

Chapter-6: KIDNEY AND UROLOGIC DISEASES AND CONDITIONS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 23 U.S. MARKET FORECAST FOR KIDNEY AND UROLOGICAL DISEASES AND INFECTIONS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 24 U.S. KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 8 SUMMARY OF KIDNEY AND UROLOGICAL DISEASES AND INFECTION MARKET BY COMPETITOR REVENUES, 2008 (%)
  • TABLE 25 MANUFACTURERS OF KIDNEY AND UROLOGIC DISEASE AND CONDITION PRODUCTS, 2008
• MARKET BY DISEASE TYPE
• URINARY TRACT INFECTIONS
• Incidence
• Diagnostics
• Market Indicators
• Market Indicators (Continued)
• URINARY INCONTINENCE
• Incidence
• Market Indicators
• Current Market Participants
  • TABLE 26 U.S. URINARY INCONTINENCE/OVERACTIVE BLADDER MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• URINARY INTERSTITIAL CYSTITIS
• Incidence
• Market Size and Growth
• IN DEVELOPMENT
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 27 KIDNEY AND UROLOGICAL DISEASE AND CONDITIONS PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
  • TABLE 27 (CONTINUED)

Chapter-7: REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 28 U.S. MARKET FORECAST FOR REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 29 U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 9 SUMMARY OF U.S. REPRODUCTIVE-RELATED THERAPEUTICS AND DIAGNOSTICS MARKET BY COMPETITOR REVENUES, 2008 (%)
• MARKET BY TYPE
• CONTRACEPTION
  • TABLE 30 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)
  • FIGURE 10 CONTRACEPTIVE USE BY METHOD FOR U.S. WOMEN AGE 15 TO 44, BY RACE, 2002 (THOUSANDS)
• Market Indicators
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Market Indicators (Continued)
• Most Commonly Used Oral Contraceptives
  • TABLE 31 MOST COMMONLY USED ORAL CONTRACEPTIVES IN THE U.S., 2008
  • TABLE 31 (CONTINUED)
• Most Commonly ..... (Continued)
• Current Market Participants
  • TABLE 32 U.S. CONTRACEPTION MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• INFERTILITY
• Incidence
• Market Indicators
• Hormonal Therapy
• Hormonal Therapy (Continued)
• Surgical Treatment
• Artificial Insemination
• Assisted Reproductive Technology
• Current Market Participants
  • TABLE 33 U.S. INFERTILITY MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• MENOPAUSE
• Incidence
• Market Indicators
• Most Commonly Used Menopause Treatment Products
  • TABLE 34 MOST COMMONLY USED MENOPAUSE TREATMENT PRODUCTS 2008
• Most Commonly ..... (Continued)
• Current Market Participants
  • TABLE 35 U.S. MENOPAUSE MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• IN DEVELOPMENT
• BAZEDOXIFENE/CONJUGATED ESTROGENS
• ALL U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 36 REPRODUCTIVE-RELATED PRODUCTS IN DEVELOPMENT IN THE U.S., 2008
  • TABLE 36 (CONTINUED)

Chapter-8: RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

• U.S. MARKET OVERVIEW
• MARKET SIZE
  • TABLE 37 U.S. MARKET FORECAST FOR RHEUMATOID ARTHRITIS AND OSTEOPOROSIS BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)
• COMPETITIVE ANALYSIS
  • TABLE 38 U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
  • FIGURE 11 SUMMARY OF U.S. RHEUMATOID ARTHRITIS AND OSTEOPOROSIS MARKET BY COMPETITOR REVENUES, 2008 (%)
  • TABLE 39 MANUFACTURERS OF RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS, 2008
  • TABLE 39 (CONTINUED)
• MARKET BY TYPE
• RHEUMATOID ARTHRITIS
• Incidence
• Market Indicators
• Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs
• Cox-2 Inhibitors
• Disease-Modifying Anti-Rheumatic Drugs
• Immunosuppressants
• Corticosteroids
• Tumor Necrosis Factor Blocker
• B-lymphocyte-Restricted Differentiation Antigen (CD20) Inhibitor
• Selective Costimulation Modulator
• Current Market Participants
  • TABLE 40 U.S. RHEUMATOID ARTHRITIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• OSTEOPOROSIS
• Incidence
• Diagnostics
• Diagnostics (Continued)
• Market Indicators
• Market Indicators (Continued)
• Current Market Participants
  • TABLE 41 U.S. OSTEOPOROSIS MARKET BY COMPETITOR REVENUE, 2008 ($ MILLIONS)
• IN DEVELOPMENT
• PREXIGE
• REMICADE
• PREOS
• ARZOXIFENE
• FABLYN
• U.S. PRODUCTS IN DEVELOPMENT
  • TABLE 42 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS PRODUCTS IN DEVELOPMENT IN U.S., 2008
  • TABLE 42 (CONTINUED)

Chapter-9: MARKET SUMMARY

• U.S. WOMEN' S HEALTHCARE MARKET ANALYSIS
  • TABLE 43 U.S. WOMEN' S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)
  • FIGURE 12 U.S. WOMEN' S HEALTHCARE DISORDER MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ MILLIONS)

Chapter-10: INDUSTRY PARTICIPANTS BY TYPE

• TABLE 44 MAJOR WOMEN' S HEALTHCARE INDUSTRY PARTICIPANTS, BY PRODUCT TYPE, 2008
• TABLE 44 (CONTINUED)
• SELECTED COMPANY PROFILES
• ASTRAZENECA
• BARR LABORATORIES, INC.
• Barr Laboratories, Inc. (Continued)
• BRISTOL-MYERS SQUIBB CO.
• ELI LILLY & CO.
• GENENTECH
• GLAXOSMITHKLINE
• MERCK & CO., INC.
• ORTHO-MCNEIL PHARMACEUTICALS
• PFIZER
• SERONO INTERNATIONAL S.A.
• WYETH
• LIST OF COMPANIES
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)
• LIST OF COMPANIES (CONTINUED)